Peña · BMC medicine 2020 · evidence-based clinical practice guideline · n=?

Adolescent polycystic ovary syndrome according to the international evidence-based guideline.

Cited 297 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Clinical practice guideline summary and expert consensus based on systematic reviews

PubMed 32204714 · doi:10.1186/s12916-020-01516-x · record verified 2026-08-26

What was done

An international panel of healthcare professionals, evidence synthesis teams, and consumers developed clinical recommendations for adolescent polycystic ovary syndrome (PCOS) using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework to appraise evidence quality, feasibility, acceptability, cost, and implementation.

What was found

The guideline establishes specific diagnostic criteria to prevent overdiagnosis: (1) menstrual irregularity defined by post-menarche timing—cycles >90 days (>1 year post-menarche), <21 or >45 days (1–3 years post-menarche), <21 or >35 days (>3 years post-menarche), or primary amenorrhea by age 15 or >3 years post-thelarche (irregularity <1 year post-menarche is considered normal development); (2) clinical (hirsutism, severe acne) or biochemical hyperandrogenism; (3) exclusion of pelvic ultrasound within 8 years post-menarche; (4) exclusion of anti-Müllerian hormone (AMH) testing; and (5) ruling out mimicking disorders. Adolescents with partial features should be categorized as 'at risk' and reassessed. Routine screening for anxiety, depression, and eating disorders is recommended, alongside lifestyle interventions, combined oral contraceptives, and/or metformin for symptom management.

Why it matters

Normal pubertal development frequently mimics adult PCOS criteria, leading to widespread misdiagnosis and unnecessary treatment. These clear post-menarche chronological cutoffs and restrictions on ultrasound and AMH establish distinct pediatric standards to avoid overdiagnosis.

Limits

The abstract does not provide the underlying search strategy, the number of primary studies reviewed, or specific quantitative effect sizes and GRADE confidence ratings for each therapeutic recommendation.

Cited by